HeyJaredPower to the Patients
Power to the Patients is a LinkedIn Live and podcast series hosted by Power where clinical research leaders across sponsors, sites, CROs, and patient advocacy groups discuss patient centricity in clinical trials.
- Indexed episodes, last 90 days
- 4
- Latest publication
- Sep 9, 2026
- Audience
- Checking…
- Earliest in this view
- Jul 7, 2026
Latest episodes
Why Enveda Teaches AI to Read Nature's Chemistry (opens the original)
Read excerpt
Isn’t it crazy to think that half of FDA-approved small molecule drugs have roots in nature? But José Trevejo, Chief Medical Officer at Enveda, says the opportunity now is not to romanticize that history, but to make it usable at modern speed. In this episode of Power to the Patients, Brandon Li speaks with José about AI-assisted drug discovery, mass spectrometry, ENV-294 and why the real bottleneck in biotech may no longer be finding molecules. It may be scaling the trials to test them. By comb
Reversing Chemo failure in ovarian cancer with Thomas Zindrick (opens the original)
Read excerpt
Platinum chemotherapy is the backbone of ovarian cancer treatment. But for far too many patients, it eventually stops working. In this episode of Power to the Patients, Brandon Li sits down with Thomas Zindrick, CEO and President of Genelux Corporation, to discuss Olvi-Vec, platinum resensitization, and why oncolytic virus therapy could give clinicians a new way to work with existing cancer treatments. Platinum resistance is one of the hardest questions to solve in clinical oncology, but some an
The Gout Narrative Keeping Patients Sick and What Crystalys Therapeutics Is Doing Differently (opens the original)
Read excerpt
Most people still think gout is a lifestyle condition caused primarily by diet. But this belief is a big reason patients have been underserved for decades. In this episode of Power to the Patients, Brandon Li sits down with James Mackay, CEO and co-founder of Crystalys Therapeutics, to explore what gout patients really need. They unpack what went wrong with Zurampic, why Dotinurad’s profile gives Crystalys Therapeutics a reason to come back to gout and how better trial design could finally move
Developing a treatment for Alzheimer's in the world of AI with Sacha Schermerhorn (opens the original)
Read excerpt
Learn about clinical trial design for small molecule therapies using biomarkers in Alzheimer's research and AI in drug development. Brandon Li talks with Sacha Schermerhorn, Founder and CEO of Babylon Biosciences. They discuss why the industry needs to rethink disease pathology, how to recruit elite talent out of retirement, and the role of fine-tuned AI models in predicting clinical outcomes for patients.
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.